Phase 2 N=18 Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
Polymyositis · Dermatomyositis
Primary: Mean Total Improvement Score (TIS) at OLE Week 48 — 36.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=98 Antibiotic "Dysbiosis" in Preterm Infants
Enterocolitis, Necrotizing · Bacteremia · Bronchopulmonary Dysplasia
Primary: Number of Events of Composite Morbidities and Mortality, Including Necrotizing Enterocolitis (NEC), Late Onset Sepsis (LOS), Bronchopulmonary Dysplasia (BPD) and Death…
Phase 2 N=105 Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Acute Myeloid Leukemia
Primary: Survival — 35; 10; 30 percentage of patients alive for one yea
Phase 2 N=58 Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
Sickle Cell Disease (SCD)
Primary: Percentage of Participants With ≥ 30% Decrease in Albuminuria (ACR) at 12 Months — 33.3; 21.4 Percentage of participants
Phase 2 N=114 Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
Hepatitis B
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment — 1; 1; 1; 1 Participants
Phase 2 N=24 Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Lung Cancer, Non-Small Cell · Metastatic Squamous Cell Carcinoma · Metastatic Non-Squamous Cell Carcinoma
Primary: Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE)…
Phase 2 N=102 A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
Treatment Resistant Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) 24 Hours — -13.7; -15.3; -13.7 score on a scale
Phase 2 N=739 Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
Rheumatoid Arthritis
Primary: Number of Participants Experiencing Treatment-Emergent Adverse Events — 453; 223 participants
Phase 2 N=26 Impact of Evolocumab in Cardiac Transplant Patients With CAV
Heart Transplant
Primary: Percent Change in Serum LDL (mg/dL) After 12 Weeks of Evolocumab — 68 percent change
Phase 2 N=24 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants
Phase 2 N=32 Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
Photoaged Skin
Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants
Phase 2 N=216 Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change in EASI From Baseline to Week 16 — -9.99; -8.83; -8.87; -9.11 score on a scale
Phase 2 N=23 Cannabidiol for ASD Open Trial
ASD · Autism Spectrum Disorder
Primary: Clinical Global Impression Scale-Improvement (CGI-I) — 3.17; 2.56; 2.25 score on a scale
Phase 2 N=23 Neoadjuvant Atezolizumab in Localized Bladder Cancer
Carcinoma, Transitional Cell
Primary: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time — -0.036; -0.041; 1.516 log2(fold change)
Phase 2 N=305 A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12 — 29.2; 35.2; 53.3; 54.2 percentage of participants…